Cargando…
Development of Orally Active Thrombin Inhibitors for the Treatment of Thrombotic Disorder Diseases
Thrombotic disorders represent the major share of the various cardiovascular diseases, and significant progress has been made in the development of synthetic thrombin inhibitors as new anticoagulants. In addition to the development of highly potent and selective inhibitors with improved safety and s...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272601/ https://www.ncbi.nlm.nih.gov/pubmed/26083038 http://dx.doi.org/10.3390/molecules200611046 |